Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 7/20 | 0.40 |
| ▸ | BCHE | P06276 | 4/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20888985 | 0.81 | ACHE (0.31) | ACHE | |
| SCHEMBL20888986 | 0.77 | — | — | |
| SCHEMBL20888662 | 0.77 | TNKS (0.34) | TNKSPARP1TNKS2 | |
| SCHEMBL20888940 | 0.75 | TNKS (0.32) | TNKSPARP1TNKS2 | |
| SCHEMBL20888942 | 0.74 | — | — | |
| Reproxalap SCHEMBL12228833 | 0.73 | TNKS (0.39) | TNKSPARP1TNKS2HTR3AHRH4 | |
| Reproxalap SCHEMBL29354850 | 0.73 | TNKS (0.39) | TNKSPARP1TNKS2HTR3AHRH4 | |
| Reproxalap SCHEMBL29536691 | 0.73 | TNKS (0.39) | TNKSPARP1TNKS2HTR3AHRH4 | |
| SCHEMBL18583115 | 0.72 | TNKS (0.44) | TNKSPARP1TNKS2HTR3AHRH4 | |
| SCHEMBL20888990 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400106-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | Aldeyra Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230149383-A1 | QUINOLINE COMPOUNDS FOR TREATING LUNG, LIVER, AND KIDNEY DISEASES, DISORDERS, OR CONDITIONS | ALDEYRA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230131929-A1 | QUINOLINE COMPOUNDS FOR TREATING RESPIRATORY DISORDERS AND VIRAL INFECTIONS | ALDEYRA THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11583529-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDEYRA THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20210393527-A1 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2021-11-18 | — | — | US | disclosed |
| US-20210347735-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-11046650-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040039-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200199075-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200038392-A1 | TOPICAL COMPOSITIONS AND METHODS OF PREPARATION AND USE | ALDEYRA THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10550085-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190105322-A1 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131929-A1 | QUINOLINE COMPOUNDS FOR TREATING RESPIRATORY DISORDERS AND VIRAL INFECTIONS | MAVS, ACE2, SARS1 | TNKS 2314/4885PARP1 810/4885TNKS2 2685/4885 |
| US-11040039-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-11583529-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-20210347735-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | TNKS 3071/4885PARP1 736/4885TNKS2 3729/4885 |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDH2, CLN6, ALDH1A1 | TNKS 4602/4885PARP1 2529/4885TNKS2 4669/4885 |
| US-10550085-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | TNKS 3071/4885PARP1 736/4885TNKS2 3729/4885 |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-20230149383-A1 | QUINOLINE COMPOUNDS FOR TREATING LUNG, LIVER, AND KIDNEY DISEASES, DISORDERS, OR CONDITIONS | GLS, PYGL, REN | TNKS 4795/4885PARP1 3708/4885TNKS2 4747/4885 |
| US-20200199075-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | TNKS 3071/4885PARP1 736/4885TNKS2 3729/4885 |
| US-20210393527-A1 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | IL5, CFTR, NQO2 | TNKS 3518/4885PARP1 3098/4885TNKS2 3950/4885 |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | TNKS 3071/4885PARP1 736/4885TNKS2 3729/4885 |
| US-20190105322-A1 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-11046650-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | TNKS 3071/4885PARP1 736/4885TNKS2 3729/4885 |
| US-20200038392-A1 | TOPICAL COMPOSITIONS AND METHODS OF PREPARATION AND USE | CUTA, TSLP, ASAH2 | TNKS 2853/4885PARP1 4447/4885TNKS2 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.